000178319 001__ 178319
000178319 005__ 20241107152052.0
000178319 0247_ $$2doi$$a10.1016/j.ejca.2021.11.030
000178319 0247_ $$2pmid$$apmid:34963094
000178319 0247_ $$2ISSN$$a0014-2964
000178319 0247_ $$2ISSN$$a0959-8049
000178319 0247_ $$2ISSN$$a1879-0852
000178319 0247_ $$2ISSN$$a(1990)
000178319 0247_ $$2ISSN$$a1879-2995
000178319 0247_ $$2ISSN$$a(1965)
000178319 0247_ $$2altmetric$$aaltmetric:119962800
000178319 037__ $$aDKFZ-2021-03266
000178319 041__ $$aEnglish
000178319 082__ $$a610
000178319 1001_ $$aKeller, Kaylee M$$b0
000178319 245__ $$aTarget Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.
000178319 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2022
000178319 3367_ $$2DRIVER$$aarticle
000178319 3367_ $$2DataCite$$aOutput Types/Journal article
000178319 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1677666264_27753$$xReview Article
000178319 3367_ $$2BibTeX$$aARTICLE
000178319 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000178319 3367_ $$00$$2EndNote$$aJournal Article
000178319 500__ $$a#EA:B062#LA:B062#
000178319 520__ $$aOwing to the high numbers of paediatric cancer-related deaths, advances in therapeutic options for childhood cancer is a heavily studied field, especially over the past decade. Classical chemotherapy offers some therapeutic benefit but has proven long-term complications in survivors, and there is an urgent need to identify novel target-driven therapies. Replication stress is a major cause of genomic instability in cancer, triggering the stalling of the replication fork. Failure of molecular response by DNA damage checkpoints, DNA repair mechanisms and restarting the replication forks can exacerbate replication stress and initiate cell death pathways, thus presenting as a novel therapeutic target. To bridge the gap between preclinical evidence and clinical utility thereof, we apply the literature-driven systematic target actionability review methodology to published proof-of-concept (PoC) data related to the process of replication stress.A meticulous PubMed literature search was performed to gather replication stress-related articles (published between 2014 and 2021) across 16 different paediatric solid tumour types. Articles that fulfilled inclusion criteria were uploaded into the R2 informatics platform [r2.amc.nl] and assessed by critical appraisal. Key evidence based on nine pre-established PoC modules was summarised, and scores based on the quality and outcome of each study were assigned by two separate reviewers. Articles with discordant modules/scores were re-scored by a third independent reviewer, and a final consensus score was agreed upon by adjudication between all three reviewers. To visualise the final scores, an interactive heatmap summarising the evidence and scores associated with each PoC module across all, including paediatric tumour types, were generated.145 publications related to targeting replication stress in paediatric tumours were systematically reviewed with an emphasis on DNA repair pathways and cell cycle checkpoint control. Although various targets in these pathways have been studied in these diseases to different extents, the results of this extensive literature search show that ATR, CHK1, PARP or WEE1 are the most promising targets using either single agents or in combination with chemotherapy or radiotherapy in neuroblastoma, osteosarcoma, high-grade glioma or medulloblastoma. Targeting these pathways in other paediatric malignancies may work as well, but here, the evidence was more limited. The evidence for other targets (such as ATM and DNA-PK) was also limited but showed promising results in some malignancies and requires more studies in other tumour types. Overall, we have created an extensive overview of targeting replication stress across 16 paediatric tumour types, which can be explored using the interactive heatmap on the R2 target actionability review platform [https://hgserver1.amc.nl/cgi-bin/r2/main.cgi?option=imi2_targetmap_v1].
000178319 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000178319 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000178319 650_7 $$2Other$$aCell cycle checkpoints
000178319 650_7 $$2Other$$aDNA repair
000178319 650_7 $$2Other$$aPaediatric oncology
000178319 650_7 $$2Other$$aPreclinical research
000178319 650_7 $$2Other$$aReplication stress
000178319 650_7 $$2Other$$aSystematic review
000178319 650_7 $$2Other$$aTargeted drugs
000178319 7001_ $$0P:(DE-He78)6e11760c6fdd0c35cd056cf36243ecd5$$aKrausert, Sonja$$b1$$eFirst author$$udkfz
000178319 7001_ $$0P:(DE-He78)60c36ed260d2d1aed48a8fab835b2990$$aGopisetty, Apurva$$b2$$udkfz
000178319 7001_ $$aLuedtke, Dan$$b3
000178319 7001_ $$aKoster, Jan$$b4
000178319 7001_ $$aSchubert, Nil A$$b5
000178319 7001_ $$aRodríguez, Ana$$b6
000178319 7001_ $$avan Hooff, Sander R$$b7
000178319 7001_ $$0P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aStichel, Damian$$b8$$udkfz
000178319 7001_ $$aDolman, M Emmy M$$b9
000178319 7001_ $$aVassal, Gilles$$b10
000178319 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b11$$udkfz
000178319 7001_ $$aCaron, Hubert N$$b12
000178319 7001_ $$aStancato, Louis F$$b13
000178319 7001_ $$aMolenaar, Jan J$$b14
000178319 7001_ $$0P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aJäger, Natalie$$b15$$eLast author$$udkfz
000178319 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b16$$eLast author$$udkfz
000178319 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2021.11.030$$gVol. 162, p. 107 - 117$$p107 - 117$$tEuropean journal of cancer$$v162$$x0014-2964$$y2022
000178319 8564_ $$uhttps://inrepo02.dkfz.de/record/178319/files/1-s2.0-S0959804921012545-main.pdf
000178319 8564_ $$uhttps://inrepo02.dkfz.de/record/178319/files/1-s2.0-S0959804921012545-main.pdf?subformat=pdfa$$xpdfa
000178319 909CO $$ooai:inrepo02.dkfz.de:178319$$pVDB
000178319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e11760c6fdd0c35cd056cf36243ecd5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000178319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)60c36ed260d2d1aed48a8fab835b2990$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000178319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d20d08adc992abdb6ccffa1686f1ba17$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000178319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000178319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bff9e3e3d86865d2b0836bb8f3ce98f3$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000178319 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000178319 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000178319 9141_ $$y2021
000178319 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000178319 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000178319 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000178319 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-30$$wger
000178319 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2021$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-30
000178319 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEUR J CANCER : 2021$$d2022-11-30
000178319 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000178319 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000178319 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x2
000178319 980__ $$ajournal
000178319 980__ $$aVDB
000178319 980__ $$aI:(DE-He78)B062-20160331
000178319 980__ $$aI:(DE-He78)HD01-20160331
000178319 980__ $$aI:(DE-He78)B300-20160331
000178319 980__ $$aUNRESTRICTED